Radium-223 dichloride for prostate cancer
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending radium-223 dichloride (Xofigo; Bayer) for treating metastatic hormone relapsed prostate cancer with bone metastases. A consultation on the guidance is available on the NICE website until 25 June 2015.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068708
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com